Towards New Uses of Botulinum Toxin as a Novel Therapeutic Tool

被引：26
作者：
Pickett, Andy [1 ]
Perrow, Karen [1 ]
机构：
[1] Ipsen Biopharm Ltd, Wrexham LL13 9UF, Wales
来源：
TOXINS | 2011年 / 3卷 / 01期
关键词：
clostridial neurotoxin; BoNT; engineering; targeting; NEUROTOXIN TYPE-A; H-C FRAGMENT; RELEASE IN-VITRO; CLOSTRIDIUM-BOTULINUM; SEROTYPE-A; TETANUS TOXIN; LIGHT-CHAIN; SUBSTRATE RECOGNITION; GENE DELIVERY; BINDING-SITE;
D O I：
10.3390/toxins3010063
中图分类号：
TS2 [食品工业];
学科分类号：
0832 ;
摘要：
The uses of botulinum toxin in the fields of neurology, ophthalmology, urology, rehabilitation medicine and aesthetic applications have been revolutionary for the treatment of patients. This non-invasive therapeutic has continually been developed since first discovered in the 1970s as a new approach to what were previously surgical treatments. As these applications develop, so also the molecules are developing into tools with new therapeutic properties in specific clinical areas. This review examines how the botulinum toxin molecule is being adapted to new therapeutic uses and also how new areas of use for the existing molecules are being identified. Prospects for future developments are also considered.
引用
收藏
页码：63 / 81
页数：19
相关论文
共 112 条
  • [1] Regulated secretion is impaired in AtT-20 endocrine cells stably transfected with botulinum neurotoxin type A light chain
    Aguado, F
    Gombau, L
    Majo, G
    Marsal, J
    Blanco, J
    Blasi, J
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (41) : 26005 - 26008
  • [2] Identification of residues surrounding the active site of type a botulinum neurotoxin important for substrate recognition and catalytic activity
    Ahmed, S. Ashraf
    Olson, Mark A.
    Ludivico, Matthew L.
    Gilsdorf, Janice
    Smith, Leonard A.
    [J]. PROTEIN JOURNAL, 2008, 27 (03) : 151 - 162
  • [3] AMBACHE N, 1951, J PHYSIOL-LONDON, V113, P1, DOI 10.1113/jphysiol.1951.sp004551
  • [4] Clostridium neurotoxin fragments as potential targeting moieties for liposomal gene delivery to the CNS
    Andreu, Alice
    Fairweather, Neil
    Miller, Andrew D.
    [J]. CHEMBIOCHEM, 2008, 9 (02) : 219 - 231
  • [5] Oncologic - Use of botulinum toxins in cancer therapy
    Ansiaux, Reginald
    Gallez, Bernard
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (02) : 209 - 218
  • [6] The use of botulinum neurotoxin type A (BoNTA) in urology
    Apostolidis, A.
    Fowler, C. J.
    [J]. JOURNAL OF NEURAL TRANSMISSION, 2008, 115 (04) : 593 - 605
  • [7] Botulinum neurotoxin type D enables cytosolic delivery of enzymatically active cargo proteins to neurones via unfolded translocation intermediates
    Bade, S
    Rummel, A
    Reisinger, C
    Karnath, T
    Ahnert-Hilger, G
    Bigalke, H
    Binz, T
    [J]. JOURNAL OF NEUROCHEMISTRY, 2004, 91 (06) : 1461 - 1472
  • [8] Botulinum neurotoxin B-host receptor recognition: it takes two receptors to tango
    Baldwin, Michael R.
    Kim, Jung-Ja P.
    Barbieri, Joseph T.
    [J]. NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2007, 14 (01) : 9 - 10
  • [9] Association of botulinum neurotoxins with synaptic vesicle protein complexes
    Baldwin, Michael R.
    Barbieri, Joseph T.
    [J]. TOXICON, 2009, 54 (05) : 570 - 574
  • [10] The C-terminus of botulinum neurotoxin type A light chain contributes to solubility, catalysis, and stability
    Baldwin, MR
    Bradshaw, M
    Johnson, EA
    Barbieri, JT
    [J]. PROTEIN EXPRESSION AND PURIFICATION, 2004, 37 (01) : 187 - 195
12345678910